 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | KARUCAN FOUNDATION [ KAFO ] |
| Street 1: | Kigoro Town Center ,Village /Parish ,Nyamwamba Division, Rukoki Sub County, Kasese Municipality Kasese District , R |
| Street 2: | Kyoho Village /Parish Bwesumbu Sub –County Busonora North County Kasese District western Region of Uganda Street: Off Kasese |
| City: | Kampala |
| Province: | Kasese District |
| Post Code: | +256 |
| Country: | Uganda |
| Phone: | +256782970397 |
| Organization Email: | karucanfoundation@gmail.com |
| Web Site: | http://.www./kimec.karucan.org |
| Other Online Presence: | YouTube: @KarucanFoundation-cr7ib |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 80034101010739 |
| Organization Type - Primary: | Non-Governmental Organization |
| Organization Type - Secondary: | Other Non-Governmental Organization (NGO) |
| Organization Description: | |
| “To facilitate communities to attain good health and livelihood through strengthened community- facilities linkage frameworks”. And we interested to be part of Stop TB Partnership in order to net work with others and resource mobilization enhancement . For Nine (9) years, KARUCAN has been involved in provision of quality health services in Kasese District, Western Uganda. In the area of TB care, KARUCAN has been active in: -Community sensitization and creating awareness about TB,TB screening and diagnosis by microscopy, Participation in Community Based Directly Observed Therapy [ CB DOT] strategy Achievements - Establishment of a community health center for treatment and prevention of common illnesses and injuries including TB - Established a diagnostic laboratory for detection of TB cases - Established integrated outreaches where TB screening, health education and prevention messages are passed onto the community |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Advocacy Civil Society and Community Engagement Delivery of health services and care Engaging political leaders and ensuring inclusive leadership Research and Development Working on Community, Rights and Gender (CRG) Working on Key Populations related to TB |
Other Organization Information | |
| Total number of staff in your organization: | 11 - 25 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | Unknown |
| How did you hear about the Stop TB Partnership: | Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | Uganda |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| For Nine (9) years, KARUCAN has been involved in provision of quality health services in Kasese District, Western Uganda. In the area of TB care, KARUCAN has been active in: -Community sensitization and creating awareness about TB,TB screening and diagnosis by microscopy, Participation in Community Based Directly Observed Therapy [ CB DOT] strategy Achievements - Establishment of a community health center for treatment and prevention of common illnesses and injuries including TB - Established a diagnostic laboratory for detection of TB cases - Established integrated outreaches where TB screening, health education and prevention messages are passed onto the community |
|
Geographical Reach | |
| Which country is your headquarters located in: | Uganda |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Unknown |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: As KARUCAN, we are planning to carry out early case detection through quality assured diagnosis. We also pllanning ot enhance political commitiment in TB Care including VHT structures. In addition we are lso planning to enhance affordable, Accessible, and free diagnostic Services including X-ray and Lab.Microscopy to TB/HIV affected Persons, if funded under TB REACH WAVE funding mechanisms In addition to the a bove, if funded, KARUCAN is planning to increase on TB are and Detectation by introducing and applying new innovotions in Kasese District Mid Western Region of Uganda as listed below: - mobile phone technology for reporting - reaching out to neglected but high risk populations (fishing communities, miners, prisons) through mobile and satellite clinics - initiating TB outreaches in hard to reach areas/ Cross boundary boarders KAsese –CUSTOMOS DRC CONGO . Screening out reaches at the boarder of kasese –drc - use of community own resource persons in identifying, referral and follow-up of TB suspects and cases - Use of TB Clients to identify and refer they fellow TB Suspects and Cases to KARUCAN Static and Outreach Sites. TB SURVIVORS Drug-Resistant TB: It is required TB-HIV: As KARUCAN Foundation [ KAFO] if funded under TB REACH WAVE funding mechanisms e are planning to contribute on this Section the following objectives and activities as mentioned below: Objective 1: Increase community access to early TB diagnosis and treatment through private health providers and mobile phone technology By increasing access, by the community to TB diagnostic services, the number of TB cases detected early will be increased. Activity 1.1 increase the private health providers’ ability to offer TB screening and diagnosis Under TB REACH, KARUCAN Foundation [ KAFO] will improve the quality of clinical services for TB screening and diagnosis through the private health facilities. These centers currently offer a wide range of clinical services including laboratory services. However, TB care services are not fully integrated and less emphasis is put on active identification of TB cases. KARUCAN shall facilitate a rapid assessment of TB services available in each facility to identify the gaps in service availability and quality, including the extent to which the services are offered in an integrated and clientele-friendly manner. Private health facilities are not always aware and may not apply the current Ministry of Health and the National TB/Leprosy Control guidelines and standards of practice (SOPs) that are essential for quality and consistent services. Therefore KARUCAN Foundation [ KAFO ] will work with its partners to orient all providers on the national and international guidelines of care for TB. To encourage sustainable quality improvement mechanisms, KARUCAN Foundation [ KAFO ] will collaborate with the District Health Teams in the respective districts including the District TB Supervisor and the Regional TB supervisor to develop a joint supportive supervision plan that outlines the role of each DHT, the partners and KAFO In collaboration with the DHT, KAFO ll participate in monthly supervision visits and technical follow-ups using this as an opportunity to coach partners on support supervision techniques and ensure that partners are applying new skills and tools to offer quality integrated services. Activity 1.2 Increase the availability of integrated TB services through Satellite Mobile Clinics at workplaces, strategic community outreach sites and prisons. Many people in these districts work in industries or workplaces without formal health services, such as fishing in Ntoroko , Katunguru , and Hamukungu, fishing sites; mining in Kasese Cobalt Company Ltd (KCCL), Hiima Cement Factory, Muhokya Lime factory and Katwe salt extraction factory. These don’t only pose an added risk for TB transmission; but these people are already loosely organised and geographically concentrated. Workplaces represent a critical and unexploited opportunity to expand TB services. Satellite or mobile clinics will be set up in these communities where people can access TB diagnosis and treatment. Also, the region has a variety of communal markets that operate in various locations on a weekly and monthly basis and daily local markets. This also provides a platform of accessing a large proportion of people in a single locality to receive TB services. Prisons health services are poorly organized and facilitated. KARUCAN will help establish TB clinics in all prisons in these districts. Activity 1.3 Empower and improve the ability of community volunteers, community adherence support agents, village health teams to report and refer suspected TB cases by Mobile Phone Technology. Community members for some reasons may not be able or willing to access health facilities or outreach sites; but can confide in community members they call their own. These people will be selected from the community to help in identifying people with symptoms of TB, collect their sputum samples and transport and or refer them to health facilities for examination. They can also trace contacts, support patients to adhere to treatment including collecting refills from the health facilities. Mobile phone software will be developed to enable them report such cases to the nearest health centre. Objective 2: strengthen TB collaboration activities Activity 2.1: Integrate TB care in routine Clinical Care, Maternal and Child Health and HIV/AIDS activities. Different people access different health services such as immunizations, family planning, Out-patient clinics. These provide avenues for screening for TB especially among children. Activity 2.2 provide isoniazide preventive therapy to PLHIV with latent TB Isoniazid shall be given to PLHIV with latent Mycobacterium tuberculosis in order to prevent progression to active disease. Latent TB shall be confirmed using mauntoux skin test. Exclusion of active TB shall be first be done using microscopy and or x-ray at or by other approved means as may be available at the time, in line with National and international guidelines. KARUCN Foundation , through TB REACH shall establish linkages and functional referral systems to the District Based Hospitals of Bwera and Bundibugyo and the regional referral hospital of Fort portal Regional Referral Hospital. Activity 2.3 Provide diagnostic HIV counseling and testing to TB patients KARUCAN shall ensure HIV counseling is offered to all TB patients and testing done to all those who consent. This shall offer an entry point for a continuum of prevention, care support and treatment for HIV/AIDS as well as for TB. Benefits of this accrue to the patient, family and the community. Laboratory Strengthening: Objective 1: Increase access to quality-assured AFB microscopy with effective external quality assurance (EQA). By the end of 2015, all of the 149 countries35 considered in the Global Plan should have at least one laboratory per 100 000 population able to perform AFB microscopy with effective EQA. More than 90% of AFB laboratories assessed for quality assurance should meet international standards. In recognition of the new technologies now available, 20% of AFB laboratories should have replaced conventional bright field microscopes with light-emitting diode (LED) microscopes. These LED microscopes enable enhanced diagnostic accuracy (and increased detection of smear-positive cases of TB) by allowing laboratory staff to visualize TB bacilli much more easily. Objective 2: Improve the diagnosis of TB among AFB smear-negative TB cases, especially among people living with HIV. A key target is to improve diagnosis of smear-negative cases by using culture and/or molecular-based tests. By 2015, the 36 countries that are in one or both lists of the 22 highburden and the 27 high MDR-TB burden countries should have at least one culture laboratory per 5 million population, or equivalent capacity to diagnose smear-negative TB using rapid molecular tests.36 New Diagnostics: Objective 1: Address existing knowledge gaps obstructing development of new diagnostic tools The development of new diagnostics poses great challenges to the scientific community, since our understanding of many of the underlying processes remains incomplete, and suitable biomarkers have yet to be identified. It is increasingly recognized that future progress in TB diagnostic development is dependent upon an expanded programme of ‘upstream’ fundamental and discovery research aimed at appropriate biomarker identification and characterisation. Objective 2: Develop a portfolio of new diagnostic tests A portfolio of projects focusing on detection of all forms of TB in all age groups, as well as MDR-TB and latent TB infection, will be established, founded on the biomarkers identified and platforms developed in Objective 1. New TB Drugs: Objective 7: Ensure the availability of clear and efficient regulatory guidelines for approval of new TB drugs and regimens, from development to registration of drugs. M New TB Vaccines: Objective 7: Build support for TB vaccine development and uptake through advocacy, communications and resource mobilization. Fundamental Research: It is required Research: It is necessary |
|
Declaration | |
| Declaration of interests: My information is correct and that there are no known conflicts of interest. | |
| Application date: | January 9, 2024 |
| Last updated: | January 9, 2024 |